Related Experiment Video
Updated: Sep 10, 2025
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.6K
Gliptin-induced Pemphigus
Avinash Jadhav1, Sandra Arora, Ashwini Dattatray Mundhe
1Department of Dermatology, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India.
Annals of African Medicine
|August 20, 2025
Summary
This case study discusses gliptin-induced pemphigus, a rare skin condition developing after starting gliptin medication for diabetes. Promptly identifying and stopping the drug is key to confirming this drug-induced pemphigus diagnosis.
Area of Science:
- Dermatology
- Endocrinology
- Pharmacology
Background:
- Pemphigus can be idiopathic or drug-induced, presenting similar clinical and histopathological features.
- Gliptins are commonly prescribed for type 2 diabetes mellitus.
- Differentiating drug-induced pemphigus from idiopathic cases is clinically significant.
Purpose of the Study:
- To report a case of gliptin-induced pemphigus.
- To emphasize the importance of a thorough medication history in diagnosing drug-induced dermatoses.
- To highlight the diagnostic criteria for drug-induced pemphigus.
Main Methods:
- A case report detailing a patient's experience with gliptin therapy and subsequent skin lesions.
- Review of clinical presentation, histopathology, and patient history.
- Assessment of lesion response following cessation of the suspected medication.
Main Results:
- The patient developed pemphigus shortly after initiating gliptin therapy.
- Clinical and histopathological findings were consistent with pemphigus.
- Skin lesions resolved after discontinuing gliptin, confirming drug-induced etiology.
Conclusions:
- Gliptin therapy can induce pemphigus, a condition that may mimic idiopathic pemphigus.
- A detailed medication history is crucial for diagnosing drug-induced pemphigus.
- Discontinuation of the causative gliptin agent leads to improvement, confirming the diagnosis.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:06Oral Hypoglycemic Agents: Glinides
257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:15Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
01:58Cell Specific Gene Expression
13.9K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.9K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K